Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Operating Leases of $47.3 million for Q1 2026, up 21.97% year-over-year from $38.8 million in Q1 2025, and down 7.07% quarter-over-quarter from $50.9 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $47.3 million for Q1 2026.
- In Q1 2026, Operating Leases rose 21.97% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (up 21.97% YoY), while the FY2025 annual figure was $50.9 million, up 30.72% from the prior year.
- Operating Leases for Q1 2026 stood at $47.3 million, down from $50.9 million in the prior quarter.
- The five-year high for Operating Leases was $83.1 million in Q1 2022, with the low at $38.8 million in Q1 2025.
- The 5-year median for Operating Leases is $61.9 million (2023), against an average of $61.4 million.
- The sharpest annual moves came in 2022 and 2025: Operating Leases sank 50.28% in 2022, then surged 30.72% in 2025.
- Jazz Pharmaceuticals' Operating Leases stood at $71.8 million in 2022, then fell by 17.56% to $59.2 million in 2023, then plunged by 34.25% to $38.9 million in 2024, then surged by 30.72% to $50.9 million in 2025, then retreated by 7.07% to $47.3 million in 2026.
- Business Quant data shows JAZZ's Operating Leases at $47.3 million in Q1 2026, $50.9 million in Q4 2025, and $53.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.60 Mn |
| Mar 31, 2026 | 47.30 Mn |
| Dec 31, 2025 | 50.90 Mn |
| Sep 30, 2025 | 53.43 Mn |
| Jun 30, 2025 | 55.11 Mn |
| Mar 31, 2025 | 38.78 Mn |
| Dec 31, 2024 | 38.94 Mn |
| Sep 30, 2024 | 71.12 Mn |
| Jun 30, 2024 | 67.62 Mn |
| Mar 31, 2024 | 56.16 Mn |
| Dec 31, 2023 | 59.23 Mn |
| Sep 30, 2023 | 61.89 Mn |
| Jun 30, 2023 | 65.55 Mn |
| Mar 31, 2023 | 72.10 Mn |
| Dec 31, 2022 | 71.84 Mn |
| Sep 30, 2022 | 72.98 Mn |
| Jun 30, 2022 | 77.85 Mn |
| Mar 31, 2022 | 83.08 Mn |
| Dec 31, 2021 | 87.20 Mn |
| Sep 30, 2021 | 106.00 Mn |